Literature DB >> 15471223

Platelet activation as a marker for in vivo prothrombotic activity: detection by flow cytometry.

A Tomer1.   

Abstract

Circulating platelets play a pivotal role in hemostasis. The platelet hemostatic function involves the direct interaction with damaged vessel walls, and circulating coagulation factors, primarily thrombin resulting in platelet activation, aggregation and formation of hemostatic plug. Flow cytometry is a useful technique for the study of platelet activation in circulating blood. Platelet activation markers for ex vivo analysis may include a) activation-dependent epitopes of the membrane glycoprotein (GP) IIb/IIIa (CD41a) receptor, as demonstrated by the binding of activation-specific monoclonal antibodies (MoAbs) PAC1, anti-LIBS1 and anti-RIBS); b) the expression of P-selectin (CD62p), the alpha-granule GP translocated to the platelet surface following release reaction; and c) platelet procoagulant activity, as demonstrated by the binding of i) annexin V protein to the prothrombinase-complex (prothrombin, activated factor X (Xa) and V (Va)) binding sites on the surface of activated platelets, and of ii) MoAbs against activated coagulation factors V and X bound to the surface of activated platelets. Using this method, platelet activation as a marker for in vivo prothrombotic activity can be demonstrated in various clinical conditions including coronary angioplasty, orthostatic challenge in primary depression, sickle cell disease in clinical remission and during pain episode, and in pregnancy-related hypertension with marked increase during preeclampsia. The finding of platelet procoagulant activity is corroborated by increased levels of plasma markers for thrombin generation and fibrinolytic activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471223

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  9 in total

1.  Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease.

Authors:  Nalini Raghavachari; Xiuli Xu; Amy Harris; Jose Villagra; Carolea Logun; Jennifer Barb; Michael A Solomon; Anthony F Suffredini; Robert L Danner; Gregory Kato; Peter J Munson; Sidney M Morris; Mark T Gladwin
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

2.  Premature labor: a state of platelet activation?

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Jawed Fareed; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Nandor Gabor Than; Edi Vaisbuch; Chong Jai Kim; Jimmy Espinoza; Pooja Mittal; Neil Hamill; Chia-Ling Nhan-Chang; Moshe Mazor; Sonia Hassan
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

3.  Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

Authors:  José Villagra; Sruti Shiva; Lori A Hunter; Roberto F Machado; Mark T Gladwin; Gregory J Kato
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

4.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

5.  The prediction of early preeclampsia: Results from a longitudinal proteomics study.

Authors:  Adi L Tarca; Roberto Romero; Neta Benshalom-Tirosh; Nandor Gabor Than; Dereje W Gudicha; Bogdan Done; Percy Pacora; Tinnakorn Chaiworapongsa; Bogdan Panaitescu; Dan Tirosh; Nardhy Gomez-Lopez; Sorin Draghici; Sonia S Hassan; Offer Erez
Journal:  PLoS One       Date:  2019-06-04       Impact factor: 3.240

6.  A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.

Authors:  Joseph A Jakubowski; Chunmei Zhou; David S Small; Kenneth J Winters; D Richard Lachno; Andrew L Frelinger; Jo Howard; Timothy G Mant; Stipo Jurcevic; Christopher D Payne
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

7.  Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mück; Stephan Schwers
Journal:  Pharmaceuticals (Basel)       Date:  2012-02-24

8.  Endothelial activation by platelets from sickle cell anemia patients.

Authors:  Renata Proença-Ferreira; Ana Flávia Brugnerotto; Vanessa Tonin Garrido; Venina Marcela Dominical; Daiana Morelli Vital; Marilene de Fátima Reis Ribeiro; Melissa Ercolin dos Santos; Fabíola Traina; Sara T Olalla-Saad; Fernando Ferreira Costa; Nicola Conran
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

9.  Comparative proteomics reveals unexpected quantitative phosphorylation differences linked to platelet activation state.

Authors:  G J Schmidt; C M Reumiller; H Ercan; U Resch; E Butt; S Heber; Z Liutkevičiūte; J Basílio; J A Schmid; A Assinger; B Jilma; M Zellner
Journal:  Sci Rep       Date:  2019-12-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.